Local and systemic effects of macrophage cytokines in intestinal inflammation

Nutrition

Volumn 14, Issue 10, 1998, Pages 780-783

  Murch, Simon H ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Growth; IL 1; IL 6; Inflammatory bowel disease; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AFFECT; ANEMIA; ANOREXIA; CONFERENCE PAPER; CROHN DISEASE; ENERGY EXPENDITURE; ENTERITIS; GROWTH INHIBITION; HUMAN; MACROPHAGE ACTIVATION; MOOD; PRIORITY JOURNAL; SLEEP DISORDER; THROMBOSIS; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; MACROPHAGE ACTIVATION; MACROPHAGES; NERVOUS SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032189705     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(98)00083-5     Document Type: Conference Paper

References (38)

1. MacDonald T.T., Murch S.H. The aetiology and pathogenesis of chronic inflammatory bowel disease. MacDonald T.T., Walker-Smith J.A. Chronic inflammatory bowel disease in childhood. Baillière's clinical gastroenterology. 1994;1 Baillière-Tindall, London.
2. Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloprotease that processes precursor tumour-necrosis factor-α Nature. 385:1997;733.
3. Chaplin D.D., Hogquist K.A. Interactions between TNF and interleukin-1. Beutler B. Tumor necrosis factors the molecules and their emerging role in medicine . 1992;197 Raven Press, New York.
4. Cominelli F., Nast C.C., Duchini A., Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory effects of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 103:1992;65.
5. van Dullemen H.M., van Deventer S.J., Hommes D.W., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 109:1995;129.
6. Murch S.H., Lamkin V.A., Savage M.O., Walker-Smith J.A., MacDonald T.T. Serum concentrations of tumour necrosis factor-alpha in childhood chronic inflammatory bowel disease. Gut. 32:1991;913.
7. Hyams J.S., Fitzgerald J.E., Treen W.R., Wyzga N., Kreutzer D.L. Relationship of functional and antigenic interleukin-6 to disease activity in inflammatory bowel disease. Gastroenterology. 104:1993;1285.
8. Murch S.H., Braegger C.P., Sessa W.C., MacDonald T.T. Increased endothelin immunoreactivity in Crohn's disease and ulcerative colitis. Lancet. 339:1992;381.
9. Colletti L.M., Remick D.G., Burtch G.D., et al. Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia-reperfusion injury in the rat. J Clin Invest. 85:1990;1936.
10. Tracey K.J., Wei H.E., Manogue K.R., et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Clin Invest. 167:1988;1211.
11. Tracey K.J., Morgello S., Koplin B., et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest. 86:1990;2014.
12. Mahmud N., O'Connell M.A., Stinson J., Goggins M.G., Weir D.G., Kelleher D. Tumour necrosis factor-α and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 7:1995;215.
13. Murch SH. Inflammatory mediators and suppression of growth in paediatric chronic IBD. In: Tytgat GNJ, Bartelsman JFWM, van Deventer SJH, eds. Inflammatory bowel diseases. Proceedings of the Falk Symposium, no. 85. Lancaster: MTP Press, 1995:598.
14. Murch S.H., MacDonald T.T., Walker-Smith J.A., Levin M., Lionetti P., Klein N.J. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet. 341:1993;711.
15. de Benedetti F., Alonzi T., Moretta A., et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1. J Clin Invest. 99:1997;643.
16. Horton J.E., Raisz L.G., Simmons H.A., Oppenheim J.S., Mergenhagen S.E. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science. 177:1972;793.
17. Raisz L.G., Luben R.A., Mundy G.R., Dietrich J.W., Horton J.E., Trummell C.L. Effect of osteoclast activating factor from human leukocytes on bone resorption. J Clin Invest. 56:1975;408.
18. Gowen M., Wood D.D., Ihrie E.J., McGuire M.K.B., Russell R.G. An interleukin-1 like factor stimulates bone resorption in vitro. Nature. 306:1983;378.
19. Mundy G.E. Effects of TNF on bone and cartilage. Beutler B. Tumor necrosis factors the molecules and their emerging role in medicine . 1992;107 Raven Press, New York.
20. Bertolini D.R., Nedwin G.E., Bringman T.S., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature. 319:1986;516.
21. Siegel S.A., Shealy D.J., Nakamada M.T., et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethally in vivo. Cytokine. 7:1995;15.
22. Pender S.L.F., Lionetti P., Murch S.H., Wathen N., MacDonald T.T. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut. 39:1996;284.
23. Pender S.L.F., Tickle S.P., Docherty A.J.P., Howie D., Wathen N.C., MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 158:1997;1582.
24. Koniaris S.G., Fisher S.E., Rubin C.T., Chawla A. Experimental colitis impairs linear bone growth independent of nutritional factors. J Pediatr Gastroenterol Nutr. 25:1997;137.
25. Ghezzi P. TNF and the liver. Beutler B. Tumor necrosis factors the molecules and their emerging role in medicine . 1992;87 Raven Press, New York.
26. Castell J.V., Gomez-Lechon M.J., David M., et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:1989;237.
27. Enerback S., Semb H., Tavernier J., et al. Tissue-specific regulation of guinea-pig lipoprotein lipase effects of nutritional state and tumor necrosis factor on mRNA levels in adipose tissue, heart and liver . Gene. 64:1988;97.
28. Ghezzi P., Saccardo B., Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P-450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun. 136:1986;316.
29. Roodman G.D. TNF and hematopoiesis. Beutler B. Tumor necrosis factors the molecules and their emerging role in medicine . 1992;117 Raven Press, New York.
30. Marsh J.A., Erf G.A. Interactions between the thyroid and the immune system. Marsh J.A., Kendall M.D. The physiology of immunity. 1996;212 CRC Press, Boca Raton, FL.
31. Roubenoff R., Roubenoff R.A., Cannon J.G., et al. Rheumatoid cachexia cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation . J Clin Invest. 93:1994;2379.
32. Heijnen C.J., Kavelaars A. Neuropeptides and the immune system. Marsh J.A., Kendall M.D. The physiology of immunity. 1996;79 CRC Press, Boca Raton, FL.
33. Brown S.L., Smith L.R., Blalock J.E. Interleukin-1 and interleukin-2 enhance pro-opiomelanocortin gene expression in pituitary cells. J Immunol. 139:1987;3181.
34. Sibinga N.E.S., Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Annu Rev Imunol. 6:1988;219.
35. Dunn A.J., Hall N.R.S. CNS biogenic amines and the immune system. Marsh J.A., Kendall M.D. The physiology of immunity. 1996;145 CRC Press, Boca Raton, FL.
36. Kapás L., Krueger J.M. Interactive effects of cytokines in the brain sleep, fever and anorexia . Marsh J.A., Kendall M.D. The physiology of immunity. 1996;157 CRC Press, Boca Raton, FL.
37. Lysle D.T., Perez L. Impact of behaviour on immunity phenomena and mechanisms . Marsh J.A., Kendall M.D. The physiology of immunity. 1996;355 CRC Press, Boca Raton, FL.
38. Ilnyckyj A., Shanahan F., Anton P.A., Cheang M., Bernstein C.N. Quantification of the placebo response in ulcerative colitis. Gastroenterology. 112:1997;1854.